Computational discovery of lead compounds targeting G1202R-based ALK triple mutations conferring lorlatinib resistance in EML4-ALK variant 3 non-small cell lung cancer.
Saved in:
| Title: | Computational discovery of lead compounds targeting G1202R-based ALK triple mutations conferring lorlatinib resistance in EML4-ALK variant 3 non-small cell lung cancer. |
|---|---|
| Authors: | Bharath, Palani1, Vignesh, Sivaprakasam1, D., Thirumal Kumar1 thirumal@maher.ac.in |
| Source: | Journal of Applied Pharmaceutical Science. Apr2026, Vol. 16 Issue 4, p304-321. 18p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
